For adult patients with moderate to severe chronic plaque psoriasis (Ps), adult patients with active psoriatic arthritis (PsA), and the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older

Access for HUMIRA patients

In 2019, over 97% of national commercial, Medicare Part D, and Medicaid patients have access to HUMIRA as a preferred, first-line* targeted immunomodulator on formulary.2

National commercial, Medicare Part D, and Medicaid health plan formulary status under the pharmacy benefit for dermatology.

In 2019, over 97% of national commercial and Medicare Part D patients have access to HUMIRA as a preferred, first-line* targeted immunomodulator (TIM) on formulary

HUMIRA (adalimumab)

National commercial, Medicare Part D, and Medicaid formulary status under the pharmacy benefit for dermatology.

*Formulary Definitions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. First-line refers to a preferred or parity formulary status.
Disadvantaged means a restriction (eg, prior authorization, step edit, quantity limits, or other medical policies) to a product that is not applied consistently across the entire therapeutic class.